儿科临床试验市场－全球产业规模、份额、趋势、机会和预测（按阶段、按研究设计、按治疗领域、按地区和竞争细分，2020-2030 年）

2024 年全球儿科临床试验市场价值为 152.9 亿美元，预计到 2030 年将达到 236.7 亿美元，预测期内复合年增长率为 7.56%。儿科临床试验专注于评估针对婴儿、儿童和青少年的药物、医疗器材和疗法的安全性、有效性和适当剂量。这些试验对于解决儿科族群特有的医疗状况和确保适合年龄的治疗至关重要。道德考虑至关重要，其协议涉及父母或监护人的知情同意。试验旨在衡量症状改善、疾病进展和安全性等结果。肺炎等儿科疾病发生率不断上升，全球每年每 10 万名儿童中就有超过 1,400 名患有肺炎，这凸显了对有针对性的治疗的迫切需求。製药公司正在优先进行儿科研究，以缩小治疗差距，特别是在南亚和撒哈拉以南非洲等高负担地区。对专业儿科护理和监管支援的需求不断增长，进一步推动了市场的发展。

关键市场驱动因素

罕见疾病日益受到关注

主要市场挑战

多样性和代表性

主要市场趋势

日益重视儿科药物研发

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球儿科临床试验市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按阶段（第一阶段、第二阶段、第三阶段和第四阶段）
  • 按研究设计（治疗研究和观察性研究）
  • 依治疗领域（呼吸系统疾病、传染病、肿瘤学、糖尿病和其他治疗领域）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：亚太地区儿科临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第七章：欧洲儿科临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第八章：北美儿科临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第九章：南美洲儿科临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲儿科临床试验市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球儿科临床试验市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Bristol-Myers Squibb Company
• . SWOT Analysis
• Charles River Laboratories International Inc.
• Covance Inc.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Inc.
• Novartis AG
• Pfizer, Inc.
• Pharmaceutical Product Development, LLC
• Syneos Health Inc.
• Paidion Research, Inc.
• The Emmes Company, LLC

第 17 章：策略建议

第18章调查会社について・免责事项

The Global Pediatric Clinical Trials Market was valued at USD 15.29 billion in 2024 and is projected to reach USD 23.67 billion by 2030, growing at a CAGR of 7.56% during the forecast period. Pediatric clinical trials focus on assessing the safety, efficacy, and appropriate dosing of drugs, medical devices, and therapies for infants, children, and adolescents. These trials are vital for addressing medical conditions unique to the pediatric population and ensuring age-appropriate treatments. Ethical considerations are paramount, with protocols involving informed consent from parents or guardians. Trials are structured to measure outcomes such as symptom improvement, disease progression, and safety. Rising pediatric disease incidence, such as pneumonia, which affects over 1,400 children per 100,000 globally each year, underscores the urgent need for targeted therapies. Pharmaceutical companies are responding by prioritizing pediatric studies to close treatment gaps, especially in high-burden regions like South Asia and Sub-Saharan Africa. Growing demand for specialized pediatric care and regulatory support further propels the market forward.

Key Market Drivers

Growing Focus on Rare Diseases

The increasing emphasis on rare or orphan diseases-many of which primarily affect children-is a major driver of pediatric clinical trials. With limited treatment options available, pediatric trials play a crucial role in drug development for these underserved conditions. Regulatory bodies such as the FDA and EMA incentivize this research through extended exclusivity periods, tax credits, and application fee waivers. Orphan drug designations can also expedite development timelines and enhance funding opportunities. In addition, patient advocacy groups actively collaborate with stakeholders to promote awareness and facilitate research efforts, thus boosting clinical trial activity in pediatric rare disease populations.

Key Market Challenges

Diversity and Representation

A major challenge in pediatric clinical trials is ensuring demographic diversity and inclusive representation. Without adequate participation from diverse racial, ethnic, and socioeconomic groups, trial results risk being non-generalizable and potentially biased. This underrepresentation can exacerbate healthcare disparities, particularly in conditions that disproportionately impact specific populations. Factors such as cultural differences, language barriers, and socioeconomic status can hinder participation, while the need for parental consent introduces additional complexity. Regulatory authorities increasingly emphasize inclusivity in trial design, and engagement with local communities is essential to building trust and overcoming recruitment challenges. Culturally competent communication strategies are critical for improving representation across pediatric studies.

Key Market Trends

Increasing Emphasis on Pediatric Drug Development

There is a growing focus on developing pediatric-specific medications, driven by both commercial potential and public health need. Advances in genomics, targeted therapies, and precision medicine are creating new pathways for pediatric drug development. Collaborative networks like the Pediatric Trials Network and the International Neonatal Consortium are supporting these efforts by pooling resources and patient data. Patient advocacy groups and global health initiatives are further amplifying awareness and support for pediatric research. These developments are accelerating clinical trial activity and fostering innovation in pediatric therapeutics, especially in areas with historically limited treatment options.

Key Market Players

• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Inc.
• Novartis AG
• Pfizer, Inc.
• Pharmaceutical Product Development, LLC
• Syneos Health Inc.
• Paidion Research, Inc.
• The Emmes Company, LLC

Report Scope:

In this report, the Global Pediatric Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Clinical Trials Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Pediatric Clinical Trials Market, By Study Design:

• Treatment Studies
• Observational Studies

Pediatric Clinical Trials Market, By Therapeutic Area:

• Respiratory Disease
• Infectious Diseases
• Oncology
• Diabetes
• Other Therapeutic Areas

Pediatric Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Clinical Trials Market.

Available Customizations:

Global Pediatric Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV)
  • 5.2.2. By Study Design (Treatment Studies and Observational Studies)
  • 5.2.3. By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Pediatric Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Therapeutic Design
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Pediatric Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Therapeutic Design
  • 6.3.2. India Pediatric Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Therapeutic Design
  • 6.3.3. Australia Pediatric Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Therapeutic Design
  • 6.3.4. Japan Pediatric Clinical Trials Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Phase
      • 6.3.4.2.2. By Study Design
      • 6.3.4.2.3. By Therapeutic Design
  • 6.3.5. South Korea Pediatric Clinical Trials Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Phase
      • 6.3.5.2.2. By Study Design
      • 6.3.5.2.3. By Therapeutic Design

7. Europe Pediatric Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Therapeutic Design
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pediatric Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Therapeutic Design
  • 7.3.2. Germany Pediatric Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Therapeutic Design
  • 7.3.3. Spain Pediatric Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Therapeutic Design
  • 7.3.4. Italy Pediatric Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Therapeutic Design
  • 7.3.5. United Kingdom Pediatric Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Therapeutic Design

8. North America Pediatric Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Therapeutic Design
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Pediatric Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Therapeutic Design
  • 8.3.2. Mexico Pediatric Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Therapeutic Design
  • 8.3.3. Canada Pediatric Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Therapeutic Design

9. South America Pediatric Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Therapeutic Design
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pediatric Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Therapeutic Design
  • 9.3.2. Argentina Pediatric Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Therapeutic Design
  • 9.3.3. Colombia Pediatric Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Therapeutic Design

10. Middle East and Africa Pediatric Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Therapeutic Design
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pediatric Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Therapeutic Design
  • 10.3.2. Saudi Arabia Pediatric Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Therapeutic Design
  • 10.3.3. UAE Pediatric Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Therapeutic Design

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pediatric Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Bristol-Myers Squibb Company
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
• 16.1.. SWOT Analysis
• 16.2. Charles River Laboratories International Inc.
• 16.3. Covance Inc.
• 16.4. GlaxoSmithKline plc
• 16.5. ICON plc
• 16.6. IQVIA Inc.
• 16.7. Novartis AG
• 16.8. Pfizer, Inc.
• 16.9. Pharmaceutical Product Development, LLC
• 16.10.Syneos Health Inc.
• 16.11.Paidion Research, Inc.
• 16.12.The Emmes Company, LLC

17. Strategic Recommendations

18. About Us & Disclaimer